全文获取类型
收费全文 | 72444篇 |
免费 | 5272篇 |
国内免费 | 1888篇 |
专业分类
耳鼻咽喉 | 432篇 |
儿科学 | 1132篇 |
妇产科学 | 1928篇 |
基础医学 | 6513篇 |
口腔科学 | 1285篇 |
临床医学 | 6326篇 |
内科学 | 6752篇 |
皮肤病学 | 574篇 |
神经病学 | 3725篇 |
特种医学 | 2176篇 |
外国民族医学 | 6篇 |
外科学 | 8385篇 |
综合类 | 12961篇 |
现状与发展 | 2篇 |
一般理论 | 11篇 |
预防医学 | 9124篇 |
眼科学 | 1048篇 |
药学 | 6238篇 |
122篇 | |
中国医学 | 8694篇 |
肿瘤学 | 2170篇 |
出版年
2024年 | 203篇 |
2023年 | 1353篇 |
2022年 | 2036篇 |
2021年 | 3422篇 |
2020年 | 3078篇 |
2019年 | 3023篇 |
2018年 | 2680篇 |
2017年 | 2593篇 |
2016年 | 2380篇 |
2015年 | 2126篇 |
2014年 | 4590篇 |
2013年 | 4457篇 |
2012年 | 3869篇 |
2011年 | 4774篇 |
2010年 | 4275篇 |
2009年 | 3279篇 |
2008年 | 3147篇 |
2007年 | 3371篇 |
2006年 | 3120篇 |
2005年 | 2635篇 |
2004年 | 2207篇 |
2003年 | 2020篇 |
2002年 | 1473篇 |
2001年 | 1233篇 |
2000年 | 1019篇 |
1999年 | 942篇 |
1998年 | 739篇 |
1997年 | 706篇 |
1996年 | 650篇 |
1995年 | 633篇 |
1994年 | 596篇 |
1993年 | 473篇 |
1992年 | 461篇 |
1991年 | 408篇 |
1990年 | 361篇 |
1989年 | 342篇 |
1988年 | 342篇 |
1987年 | 297篇 |
1986年 | 264篇 |
1985年 | 480篇 |
1984年 | 477篇 |
1983年 | 368篇 |
1982年 | 407篇 |
1981年 | 387篇 |
1980年 | 392篇 |
1979年 | 329篇 |
1978年 | 294篇 |
1977年 | 258篇 |
1976年 | 196篇 |
1975年 | 121篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Objective
The aim of the study was to estimate the effect of the state-based reinsurance programs through the section 1332 State Innovation Waivers on health insurance marketplace premiums and insurer participation.Data Source
2015 to 2022 Robert Wood Johnson Foundation Health Insurance Exchange Compare Datasets.Study Design
An event study difference-in-differences (DD) model separately for each year of implementation and a synthetic control method (SCM) are used to estimate year-by-year effects following program implementation.Data Collection/Extraction Methods
Not applicable.Principal Findings
Reinsurance programs were associated with a decline in premiums in the first year of implementation by 10%–13%, 5%–19%, and 11%–17% for bronze, silver, and gold plans (p < 0.05). There is a trend of sustained declines especially for states that implemented their programs in 2019 and 2020. The SCM analyses suggest some effect heterogeneity across states but also premium declines across most states. There is no evidence that reinsurance programs affected insurer participation.Conclusion
State-based reinsurance programs have the potential to improve the affordability of health insurance coverage. However, reinsurance programs do not appear to have had an effect on insurer participation, highlighting the need for policy makers to consider complementary strategies to encourage insurer participation. 相似文献2.
3.
4.
In clinical and epidemiological studies, there is a growing interest in studying the heterogeneity among patients based on longitudinal characteristics to identify subtypes of the study population. Compared to clustering a single longitudinal marker, simultaneously clustering multiple longitudinal markers allow additional information to be incorporated into the clustering process, which reveals co-existing longitudinal patterns and generates deeper biological insight. In the current study, we propose a Bayesian consensus clustering (BCC) model for multivariate longitudinal data. Instead of arriving at a single overall clustering, the proposed model allows each marker to follow marker-specific local clustering and these local clusterings are aggregated to find a global (consensus) clustering. To estimate the posterior distribution of model parameters, a Gibbs sampling algorithm is proposed. We apply our proposed model to the primary biliary cirrhosis study to identify patient subtypes that may be associated with their prognosis. We also perform simulation studies to compare the clustering performance between the proposed model and existing models under several scenarios. The results demonstrate that the proposed BCC model serves as a useful tool for clustering multivariate longitudinal data. 相似文献
5.
6.
7.
8.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
9.
《Journal of pediatric surgery》2023,58(5):856-861
Background/PurposeA small number of Hirschsprung disease (HD) patients develop inflammatory bowel disease (IBD)-like symptoms after pullthrough surgery. The etiology and pathophysiology of Hirschsprung-associated IBD (HD-IBD) remains unknown. This study aims to further characterize HD-IBD, to identify potential risk factors and to evaluate response to treatment in a large group of patients.MethodsRetrospective study of patients diagnosed with IBD after pullthrough surgery between 2000 and 2021 at 17 institutions. Data regarding clinical presentation and course of HD and IBD were reviewed. Effectiveness of medical therapy for IBD was recorded using a Likert scale.ResultsThere were 55 patients (78% male). 50% (n = 28) had long segment disease. Hirschsprung-associated enterocolitis (HAEC) was reported in 68% (n = 36). Ten patients (18%) had Trisomy 21. IBD was diagnosed after age 5 in 63% (n = 34). IBD presentation consisted of colonic or small bowel inflammation resembling IBD in 69% (n = 38), unexplained or persistent fistula in 18% (n = 10) and unexplained HAEC >5 years old or unresponsive to standard treatment in 13% (n = 7). Biological agents were the most effective (80%) medications. A third of patients required a surgical procedure for IBD.ConclusionMore than half of the patients were diagnosed with HD-IBD after 5 years old. Long segment disease, HAEC after pull through operation and trisomy 21 may represent risk factors for this condition. Investigation for possible IBD should be considered in children with unexplained fistulae, HAEC beyond the age of 5 or unresponsive to standard therapy, and symptoms suggestive of IBD. Biological agents were the most effective medical treatment.Level of EvidenceLevel 4 相似文献
10.